Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: A report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire

Bone Marrow Transplantation

Volumn 49, Issue 3, 2014, Pages 382-388

  De Berranger, E ^a   Cousien, A ^b   Petit, A ^c   Peffault De Latour, R ^d   Galambrun, C ^e   Bertrand, Y ^f   Salmon, A ^g   Rialland, F ^h,i   Rohrlich, P S ^j   Vannier, J P ^k   Lutz, P ^l   Yakouben, K ^m   Duhamel, A ^b   Bruno, B ^a   Michel, G ^e   Dalle, J H ^m,n  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e TIMONE HOSPITAL   (France)

^f IHOP   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITÉ DE NANTES   (France)

^j UNIVERSITY HOSPITAL OF BESANÇON   (France)

^k ROUEN UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^m HÔPITAL ROBERT DEBRÉ   (France)

ⁿ CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

more..

Author keywords

AML; children; conditioning; overall; transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PROGNOSIS; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; HLA MATCHING; HUMAN; LEUKEMIA RELAPSE; LIVING DONOR; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNRELATED DONORS; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; BODY WEIGHT; CHEMISTRY; DONOR; FRANCE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MEDICAL SOCIETY; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; PROCEDURES; RECURRENT DISEASE; REGISTER; SIBLING; TREATMENT OUTCOME;

ADOLESCENT; BODY WEIGHT; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; FRANCE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MULTIVARIATE ANALYSIS; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; SIBLINGS; SOCIETIES, MEDICAL; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 84904240087     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.185     Document Type: Article

References (39)

1. Entz-Werle N, Suciu S, van der Werff ten Bosch J, Vilmer E, Bertrand Y, Benoit Y et al. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia 2005; 19: 2072-2081.
2. Perel Y, Auvrignon A, Leblanc T, Michel G, Reguerre Y, Vannier JP et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit-multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group. Leukemia 2005; 19: 2082-2089.
3. Perel Y, Auvrignon A, Leblanc T, Vannier JP, Michel G, Nelken B et al. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucamie Aique Myeloide Enfant. J Clin Oncol 2002; 20: 2774-2782.
4. Vettenranta K. Current European practice in pediatric myeloablative conditioning. Bone Marrow Transplant 2008; 41(Suppl 2): S14-S17.
5. Michel G, Gluckman E, Esperou-Bourdeau H, Reiffers J, Pico JL, Bordigoni P et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation-a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 1994; 12: 1217-1222.
6. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009; 114: 2489-2496.
7. Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK et al. Cyto-genetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010; 28: 2674-2681.
8. Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2009; 113: 6558-6566.
9. Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006; 108: 3654-3661.
10. Meshinchi S, Arceci RJ, Sanders JE, Smith FO, Woods WB, Radich JP et al. Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood 2006; 108: 400-401.
11. von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010; 28: 2682-2689.
12. Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR. Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. Biol Blood Marrow Transplant 2013; 19: 1021-1025.
13. Gassas A, Ishaqi MK, Afzal S, Finkelstein-Shechter T, Dupuis A, Doyle J. A comparison of the outcomes of children with acute myelogenous leukemia in either first or second complete remission (CR1 vs CR2) following allogeneic hemato-poietic stem cell transplantation at a single transplant center. Bone Marrow Transplant 2008; 41: 941-945.
14. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
15. Leblanc T, Le Coniat M, Flexor M, Baruchel A, Daniel MT, Berger R. An interstitial 11q23 deletion proven to be a rearrangement interrupting the MLL gene in an infant with acute myeloblastic leukemia. Leukemia 1996; 10: 1844-1846.
16. Belkacemi Y, Rio B, Touboul E. Total body irradiation: techniques, dosimetry, and complications. Cancer Radiother 1999; 3: 162-173.
17. Vassal G, Michel G, Esperou H, Gentet JC, Valteau-Couanet D, Doz F et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008; 61: 113-123.
18. Labopin M, Iacobelli S. Statistical guidelines for EBMT. 2003; Available at http://portal.ebmt.org/sites/clint2/clint/Documents/StatGuidelines-oct2003. pdf.
19. Klingebiel T, Reinhardt D, Bader P. Place of HSCT in treatment of childhood AML. Bone Marrow Transplant 2008; 42(Suppl 2): S7-S9.
20. Oliansky DM, Rizzo JD, Aplan PD, Arceci RJ, Leone L, Ravindranath Y et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2007; 13: 1-25.
21. Niewerth D, Creutzig U, Bierings MB, Kaspers GJ. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 2010; 116: 2205-2214.
22. Sisler IY, Koehler E, Koyama T, Domm JA, Ryan R, Levine JE et al. Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study. Biol Blood Marrow Transplant 2009; 15: 1620-1627.
23. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
24. Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997; 20: 909-913.
25. Shi-Xia X, Xian-Hua T, Hai-Qin X, Bo F, Xiang-Feng T. Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis. Leuk Lymphoma 2010; 51: 50-60.
26. Ferry C, Socie G. Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: what have we learned? Exp Hematol 2003; 31: 1182-1186.
27. Shenoy S, Smith FO. Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin. Bone Marrow Transplant 2008; 41: 141-148.
28. Willemze AJ, Geskus RB, Noordijk EM, Kal HB, Egeler RM, Vossen JM. HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: less relapse with higher biologically effective dose of TBI. Bone Marrow Transplant 2007; 40: 319-327.
29. Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C et al. Standard versus alternative myeloablative conditioning regimens in allogeneic hemato-poietic stem cell transplantation for high-risk acute leukemia. Haematologica 2002; 87: 52-58.
30. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
31. Michel G, Socie G, Gebhard F, Bernaudin F, Thuret I, Vannier JP et al. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation-a report from the Societe Francaise de Greffe de Moelle. J Clin O 1997; 15: 2238-2246.
32. Petropoulos D, Worth LL, Mullen CA, Madden R, Mahajan A, Choroszy M et al. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies. Bone Marrow Transplant 2006; 37: 463-467.
33. Socie G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001; 98: 3569-3574.
34. Oudin C, Simeoni MC, Sirvent N, Contet A, Begu-Le Coroller A, Bordigoni P et al. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood 2011; 117: 4442-4448.
35. Inagaki J, Nagatoshi Y, Sakiyama M, Nomura Y, Teranishi H, Sasaki T et al. TBI and melphalan followed by allogeneic hematopoietic SCT in children with advanced hematological malignancies. Bone Marrow Transplant 2011; 46: 1057-1062.
36. Kroger N, Zabelina T, Sonnenberg S, Kruger W, Renges H, Stute N et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclopho-sphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow Transplant 2000; 26: 711-716.
37. Worth L, Tran H, Petropoulos D, Culbert S, Mullen C, Roberts W et al. Hemato-poietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide. Bone Marrow Transplant 1999; 24: 947-952.
38. Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA et al. Non-myeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 2859-2867.
39. Mohty M, de Lavallade H, Ladaique P, Faucher C, Vey N, Coso D et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005; 19: 916-920.